Objective: Effective strategies to reduce costs associated with endovascular aneurysm repair (EVAR) remain elusive for many medical centers. In this study, targeted interventions to reduce inpatient EVAR costs were identified and implemented.
In 2014, The Society for Vascular Surgery (SVS) Patient Safety Organization (PSO) embarked on a major initiative to address the value of endovascular aneurysm repair (EVAR). 1, 2 This EVAR Cost Reduction Project integrated hospital billing data with clinical quality data at 18 Vascular Quality Initiative (VQI) hospitals to evaluate variation in both cost and quality data. This undertaking allowed participating hospitals to benchmark costs and to identify potential areas of savings. The pilot project also reported that EVAR costs frequently exceeded Medicare reimbursements, confirming that for a majority of institutions, EVAR is associated with negative operating margins, 3, 4 thus threatening the sustainability of these procedures for many health care organizations. As a participating institution in this project, we recognized that our EVAR-associated costs were higher than those accrued at peer institutions nationwide. As a result, several steps were undertaken to reduce these costs, including identifying improvement opportunities and implementing institution-specific interventions to reduce spending while maintaining quality outcomes. This report outlines the processes undertaken to improve the value of EVAR as a result of this exercise.
METHODS
This study examined EVAR-related expenses for adult patients $18 years of age hospitalized at a 613-bed academic medical center during two specific sequential time periods. Individuals were included in the study if they had an inpatient admission with Medicare Severity Diagnosis Related Group code 237, 238, 268, or 269 and International Classification of Diseases, Ninth Revision code 39.71 or 39.78 or International Classification of Diseases, Tenth Revision code 04U03JZ, 04U04JZ, 04V03DZ, or 04V04DZ and a discharge physician in the Division of Vascular Surgery. A baseline analysis of per-patient direct costs to Stanford Health Care was conducted using retrospective claims data from September 2013 to May 2015. From June 2015 to February 2016, we implemented improvement projects in the three categories that accounted for a majority of costs. Postintervention (POST) direct costs were collected from March 2016 to January 2017 and compared with the baseline, preintervention (PRE) period.
The study was submitted to the Stanford University Institutional Review Board, which waived the requirement for informed consent on the basis of the type of data analyzed and method of acquisition (IRB-44109).
Data sources. Hospital direct costs, demographic data, encounter diagnoses, and primary procedure attending physician were obtained from the hospital's financial database system, a decision support and cost accounting system that integrates billing and gain/loss data to calculate hospital costs on a per-patient, per-case, and per-unit basis. Several studies have previously used similar strategies to estimate the costs of health care services at individual hospitals. [5] [6] [7] Hospital costs included the sum of actual direct costs (not billed charges) for all services including room accommodations, procedural room time, medications, medical and surgical supplies, laboratory and imaging, and other ancillary services. Emergency department costs were included if an individual was admitted to the hospital through the emergency department. Length of stay (LOS) benchmark data were pulled from the Clinical Data Base Resource Manager application owned and managed by Vizient Inc (Irving, Tex), a consortium of member academic medical centers that shares quality, operational, and cost information for the purposes of benchmarking and improvement. The LOS index is the observed LOS compared with the expected LOS, based on reason for hospitalization and the patient's comorbidities. Intraoperative and postoperative details, including complications, were queried using the institution's VQI database and Medicare Severity Diagnosis Related Group billing codes.
Interventions. Vascular surgeons collaborated with the institutional High Value Care (HVC) team to identify areas of cost reduction. The HVC team was composed of a financial analyst, staff members, and physician administrator who worked on concurrent cost reduction projects across specialties. Vascular surgeons invested 2 to 3 hours per month on this project during the assessment and planning phases. In the preintervention cohort, the major components of cost were medical and surgical supplies, including implant costs (52.6%), bed costs (14.7%), operating room-related costs (14.6%), and imaging (7.3%; Fig) . The HVC team developed interventions that were concentrated on the top three drivers of inpatient costs under the surgeon's control: device costs, preprocedural admissions, and inpatient radiology volume.
Quality department improvement specialists designed Plan-Do-Study-Act improvement cycles to analyze baseline use, to determine current-state and ideal-state frontline provider workflows, to execute improved workflows, to collect data on performance, and to adjust workflows as needed. Vascular surgeons met with HVC team representatives monthly to plan interventions and to review results. Ongoing hospital projects including pharmacy cost reduction were being implemented in parallel with the vascular surgery division efforts. This included using generic pharmaceuticals where possible and transitioning to lower cost intravenous drugs used during anesthesia and the postoperative period.
Intervention 1: Device costs. Based on data obtained through the SVS PSO EVAR Cost Demonstration Project, it was determined that implantable device costs were higher than those at peer institutions. Working with hospital purchasing staff and an external consulting company, new purchasing strategies were implemented, including rebates for high-volume use and capped costs for complex cases. The consulting company had national pricing data to leverage negotiations for lower device costs with vendors.
Intervention 2: Preprocedural admissions. Given the geographic range of our practice in northern and central California, many patients travel significant distances for elective and urgent abdominal aortic aneurysm (AAA) care. In previous practice, patients traveling long distances the day before surgery were often admitted for a 23-hour preprocedure stay to ensure readiness for surgery the following morning. This analysis determined that costs accrued during this preprocedure admission were frequently not reimbursed. Clinical criteria allowing reimbursement for preprocedural admission were developed, including need for prehydration in patients with chronic renal insufficiency.
ARTICLE HIGHLIGHTS
Hospital LOS after EVAR was not identified as a significant intervention as our LOS index compared favorably with regional benchmarks. In calendar year 2014, our LOS observed to expected index, compared with other academic medical centers in California, was 0.74 for patients with standard grafts and 0.54 for patients with fenestrated or branching grafts. These patterns persisted in the first half of 2015 (Supplementary Table, online only).
Intervention 3: Inpatient radiology costs. In previous practice, computed tomography (CT) scans were frequently obtained during the index hospitalization to maximize the patient's compliance with the need for baseline postoperative imaging. As a result of the implemented cost-saving strategies, inpatient CT scans after EVAR were not performed unless medically indicated. Instead, telephone follow-up was more frequently used with patients, and when appropriate, the initial postprocedural CT scan was performed closer to the patient's home on an outpatient basis. When examined more closely, the balance of imaging expenses was related to postprocessing costs after three-dimensional (3D) image reformatting. As part of an evidence-based standardized care path, we developed clinical criteria to determine patients who required postprocessing 3D reconstruction for images acquired during the index hospitalization. We worked with the radiology department to discontinue protocol postprocessing 3D reconstruction of abdominal/pelvic post-EVAR CT imaging studies without a specific surgeon-generated request. We also worked with our information technology department to generate electronic health record order sets that allowed elective authorization of postprocessing 3D reconstruction and educated all trainees, nurse practitioners, and faculty on this new process.
Study variables. We examined patient and hospitalization characteristics, including admission source, admitting service, services used during admission, direct costs of services used, LOS, and case mix index. 8 The patients' medical records were queried to determine elective vs nonelective EVAR, the latter group defined as symptomatic or ruptured AAAs. We categorized EVAR procedures as either standard infrarenal repair or complex, the latter defined as procedures requiring fenestrated or parallel graft strategies for management of the proximal neck or ancillary procedures to preserve internal iliac perfusion. Complications incurred during the index hospitalization, including reinterventions, were investigated using the institution's VQI database. 2 The faculty roster of surgeons involved did not change between the PRE and POST periods.
Data analysis. The primary outcome of interest was the direct costs of services used. Univariable logistic regression was first applied to determine potential associations between study variables and the primary outcome of interest. Standard 
RESULTS
Our cohort comprised 141 PRE and 47 POST patients. Table I shows patients' characteristics between cohorts. Age, sex, urgency of the surgery, and insurance type were similar between cohorts. Case mix index was significantly higher in the POST cohort (P < .001), with the percentage of complex cases increasing from 36.9% to 44.7%. Overall, average per-patient inpatient direct costs for cases with complex repairs were 35.8% (P < .001) higher than standard EVAR procedures.
Targeted cost reduction efforts led to significant savings. Restructuring of EVAR device contracts resulted in a 30.8% decrease in per-case device costs between the PRE and POST periods (intervention 1). By implementation of standardized clinical criteria for preprocedural "short-stay" admissions, use decreased by 50% (35.4% PRE to 17.0% POST; P ¼ .021) without having a significant impact on operative readiness or the average postprocedural LOS (PRE, 3.0 6 2.5 days; POST, 2.6 6 2.5 days; P ¼ .185). This led to a 35.2% reduction in direct room costs (P ¼ .101; intervention 2). Compared with baseline, per-case imaging costs decreased by 93.3% (P < .001), including a 99.1% (P ¼ .001) reduction in postprocessing costs (intervention 3). A byproduct of hospital-wide care path implementation was a 38.3% reduction (P < .001) in costs related to inpatient medication use for EVAR patients (Table II) .
Analysis of intraoperative procedural variables demonstrated no statistically significant difference between procedure time, estimated blood loss, iodinated contrast material use, and need for or number of units of blood transfused (Table III) . Complications were noted in 12.8% of patients in the PRE period vs 17.0% of patients in the POST period (P ¼ .47), with no statistically significant difference between the type of complications incurred in either period (Table III) . The LOS, ICU admission requirements, and likelihood of discharge home after the procedure were similar between the two periods (Table III) . The hospital LOS was shorter for elective (2.6 6 0.6 days) vs nonelective procedures (5.4 6 4.0 days; P < .001). The hospital LOS was also shorter for standard procedures (2.3 6 2.5 days) compared with complex procedures (3.4 6 2.6 days; P ¼ .037).
DISCUSSION
As EVAR has become the referent method of AAA repair in the United States, 9 This experience confirms that substantial EVAR-related savings are attainable through focused cost reduction efforts. To our knowledge, this is the first reported implementation of cost reduction strategies identified through SVS PSO Cost Demonstration Projects. Targeted areas of process improvement resulted in a 30.8% per-case reduction in device costs and decreases in inpatient radiology imaging costs and preprocedural rooming costs. This report adds to a growing literature of interventions identified to improve the value and sustainability of EVAR nationwide. 12, 13 Although current VQI membership does not provide procedural cost and reimbursement analyses across participating centers outside of the Cost Demonstration Project framework, benchmarking of clinical outcomes allows identification of improvement opportunities across all sites. Since its inception, graft costs have been the main determinant of hospital expenses related to EVAR. 14, 15 Unfortunately, graft costs continue to increase despite an ever-expanding marketplace of approved devices. Price transparency can reduce costs, as reflected by the SVS PSO EVAR Cost Demonstration Project, by providing price benchmarking to guide negotiations with vendors. To balance endografts' development costs with sustainability considerations, transparency and open dialogue will remain essential in the years going forward.
In comparing standard vs complex EVAR, not surprisingly, complex procedures were substantially more expensive. Previous studies have clearly linked anatomic [16] [17] [18] Fenestrated or branched EVAR procedures entail greater risks for serious complications and attendant hospital costs. 19, 20 More research is needed to define cost-effectiveness as a function of procedural complexity, particularly for high-volume centers to which these patients are usually referred.
Imaging accounted for a significant fraction of total procedural costs at our institution. As incident reimbursement for each hospitalization is capped within a single diagnosis-related group designation, postprocedural imaging may have a significant impact on finances when it is obtained during the index hospitalization. In our practice, in general, once the initial postoperative CT scan identifies an optimal procedural result (good graft position, no type IA or IB endoleaks, normal distal perfusion), follow-up surveillance is primarily ultrasound based, with further CT scans reserved for patients with enlarging AAAs or otherwise problem clinical conditions that limit the utility of ultrasound (eg, excessive body mass index). As postoperative imaging may be financially beneficial for institutions, 13 these revenue opportunities need to be weighed against the overall societal costs for postoperative surveillance. 21, 22 We were able to decrease preprocedural hospitalization by narrowing criteria for short-stay admissions and organizing practical alternative options for eligible patients. These changes did not have a negative impact on our overall postprocedure hospital LOS. Current trials are examining the feasibility and safety of same-day EVAR, 23, 24 although existing Medicare reimbursement policies do not incentivize hospitals to discharge EVAR patients <24 hours after the procedure. As the trend toward outpatient endovascular intervention continues to accelerate, reconsideration of the appropriateness of <24-hour stays after EVAR will be inevitable. This study has several limitations warranting further consideration. The results obtained at a single academic medical center may not be generalizable to other health care organizations across the United States. Hospitals with smaller procedural volumes may have less ability to negotiate substantial discounts with vendors. In addition, direct costs and financial consequences were not accounted for beyond the index hospitalization. Outcomes were reported as percentage improvements (rather than specific dollar amounts) to avoid adverse influences on reimbursements provided by local insurers for services rendered, which if incurred would hamper further cost reduction efforts at our institution. Finally, our analyses were derived from hospital administrative claims data rather than direct cost accounting, and institutional variability in these methods may limit the generalizability of these results.
From planning to implementation, this project required 7 months of dedicated time and coordinated effort from multiple administrative units of a large health care organization. Participation in the SVS PSO EVAR Cost Demonstration Project identified the opportunity, and enthusiastic participation by the vascular surgeons enabled rapid adoption and change. Informing physicians of the elements of procedural expense and engaging their participation in cost reduction opportunities are both important steps in improving the value of vascular disease care 25, 26 as well as the sustainability of the American health care system overall.
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CONCLUSIONS
Excessive EVAR-associated costs threaten the viability of this AAA management method in many health care organizations. We leveraged institutional resources to significantly reduce EVAR-related expenses without compromising quality outcomes or patients' access. Beyond EVAR, similar value improvement opportunities exist for many other vascular-related interventions, and future SVS PSO efforts should be directed toward identifying and reducing excessive costs associated with procedural management of all aspects of vascular disease. Additional material for this article may be found online at www.jvascsurg.org.
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INVITED COMMENTARY
Andres Schanzer, MD, Worcester, Mass During the last three decades, vascular surgeons have successfully introduced and embraced a new, minimally invasive approach for the treatment of abdominal aortic aneurysms using endovascular aneurysm repair (EVAR). Whereas countless patients have benefited from EVAR, it is not without its limitations, which include a critical need for lifelong follow-up, a significant reintervention rate that does not plateau over time, and the increased cost.
In this month's Journal of Vascular Surgery, Itoga and colleagues take an important step toward developing strategies to mitigate the costs associated with EVAR treatment. They target three primary drivers of cost: device costs, radiology costs, and preprocedure admission costs. The last two are easily addressed and generalizable (radiology costs: decrease the number of computed tomography scans when possible and do not order three-dimensional postprocessing unless necessary; preprocedure admission costs: do not admit patients before the day of surgery). However, bringing device costs down remains a significant challenge for many institutions.
As previous publications have shown, the primary driver of cost in their study is attributable to the EVAR device. 1 What is unique and important about this study is the way in which they went about trying to reduce their device costs using the Vascular Quality Initiative (VQI). Whereas the VQI has previously been demonstrated to be a powerful engine for collaborative research and measuring quality by benchmarking risk-adjusted outcomes between sites and regions, before this study, the VQI has not been used as a tool for cost containment. By leveraging the VQI platform, 18 sites participated in the Society for Vascular Surgery EVAR Cost Demonstration Project and shared cost data. 2 This effort revealed threefold variation in EVAR device costs across sites and enabled the authors' institution to engage in aggressive, informed negotiations with vendors, resulting in a 31% reduction in device costs per case. Given the thin margins associated with EVAR, a 31% reduction in device costs can be the key difference in the procedure's yielding a positive contribution margin (eg, profit) or a negative contribution margin (eg, loss). This study also highlights an important paradigm change that is occurring at more and more centers across the United States: physicians need to play an active role in the effort to reduce costs.
